-
1
-
-
85039751538
-
9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018
-
American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(suppl 1):S86-S104.
-
(2018)
Diabetes Care
, vol.41
, pp. S86-S104
-
-
-
2
-
-
85062798455
-
-
Guidance For Industry Diabetes Mellitus - Evaluating Cardiovascular Risk In New Antidiabetic Therapies To Treat Type 2 Diabetes., Accessed November 15
-
U.S. Food and Drug Administration. Guidance For Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk In New Antidiabetic Therapies To Treat Type 2 Diabetes. https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf. Accessed November 15, 2018.
-
(2018)
-
-
-
3
-
-
85019567375
-
More than 7 years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications
-
Regier EE, Venkat MV, Close KL. More than 7 years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications. Clin Diabetes. 2016;34:173-180.
-
(2016)
Clin Diabetes
, vol.34
, pp. 173-180
-
-
Regier, E.E.1
Venkat, M.V.2
Close, K.L.3
-
4
-
-
85038951494
-
Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' expert forum
-
Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' expert forum. Diabetes Care. 2018;41:14-31.
-
(2018)
Diabetes Care
, vol.41
, pp. 14-31
-
-
Cefalu, W.T.1
Kaul, S.2
Gerstein, H.C.3
-
5
-
-
85062771238
-
-
To_Data. IQVIA Real-World Data Adjudicated Claims., Accessed November 15
-
B.R.I.D.G.E To_Data. IQVIA Real-World Data Adjudicated Claims. https://www.bridgetodata.org/node/824. Accessed November 15, 2018.
-
(2018)
-
-
-
6
-
-
85062778134
-
-
Facts for Features Older Americans Month May 2017, Accessed November 15
-
United States Census Bureau. Facts for Features: Older Americans Month: May 2017 https://www.census.gov/newsroom/facts-for-features/2017/cb17-ff08.html. Accessed November 15, 2018.
-
(2018)
-
-
-
7
-
-
85062800304
-
-
National Health and Nutrition Examination Survey., Accessed November 15
-
Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. https://www.cdc.gov/nchs/nhanes/index.htm. Accessed November 15, 2018.
-
(2018)
-
-
-
8
-
-
85018965453
-
Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999-2010
-
Zhang N, Yang X, Zhu X, Zhao B, Huang T, Ji Q. Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999-2010. J Int Med Res. 2017;45:594-609.
-
(2017)
J Int Med Res
, vol.45
, pp. 594-609
-
-
Zhang, N.1
Yang, X.2
Zhu, X.3
Zhao, B.4
Huang, T.5
Ji, Q.6
-
9
-
-
85065680992
-
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population
-
Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018;24(suppl 8):S146-S155.
-
(2018)
Am J Manag Care
, vol.24
, pp. S146-S155
-
-
Wittbrodt, E.T.1
Eudicone, J.M.2
Bell, K.F.3
Enhoffer, D.M.4
Latham, K.5
Green, J.B.6
-
10
-
-
85011676254
-
Trends in dietary intake among adults with type 2 diabetes: NHANES 1988-2012
-
Casagrande SS, Cowie CC. Trends in dietary intake among adults with type 2 diabetes: NHANES 1988-2012. J Hum Nutr Diet. 2017;30:479-489.
-
(2017)
J Hum Nutr Diet
, vol.30
, pp. 479-489
-
-
Casagrande, S.S.1
Cowie, C.C.2
-
11
-
-
85062800063
-
-
Overview of NHANES Survey Design and Weights., Accessed November 15
-
Centers for Disease Control and Prevention. Overview of NHANES Survey Design and Weights. https://www.cdc.gov/nchs/tutorials/environmental/orientation/sample_design/. Accessed November 15, 2018.
-
(2018)
-
-
-
12
-
-
85062776092
-
-
Accessed November 15,, https://clinicaltrials.gov
-
U.S. National Library of Medicine. ClinicalTrialsgov https://clinicaltrials.gov. Accessed November 15, 2018.
-
(2018)
-
-
-
13
-
-
27144439138
-
Standard deviations and standard errors
-
Altman DG, Bland JM. Standard deviations and standard errors. BMJ. 2005;331:903.
-
(2005)
BMJ
, vol.331
, pp. 903
-
-
Altman, D.G.1
Bland, J.M.2
-
14
-
-
85023614886
-
Design and baseline characteristics of participants in the researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
-
Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20:42-49.
-
(2018)
Diabetes Obes Metab
, vol.20
, pp. 42-49
-
-
Gerstein, H.C.1
Colhoun, H.M.2
Dagenais, G.R.3
-
15
-
-
85030448557
-
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
-
Protocol for
-
Protocol for:Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-1239.
-
(2017)
N Engl J Med
, vol.377
, pp. 1228-1239
-
-
Holman, R.R.1
Bethel, M.A.2
Mentz, R.J.3
-
16
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
Protocol for
-
Protocol for:Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2016;375:311-322.
-
(2016)
New Engl J Med.
, vol.375
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
-
17
-
-
84994813253
-
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
-
Supplement to
-
Supplement to:Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
-
(2016)
N Engl J Med
, vol.375
, pp. 1834-1844
-
-
Marso, S.P.1
Bain, S.C.2
Consoli, A.3
-
18
-
-
84977480444
-
Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial
-
Holman RR, Bethel MA, George J, et al. Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial. Am Heart J. 2016;174:103-110.
-
(2016)
Am Heart J
, vol.174
, pp. 103-110
-
-
Holman, R.R.1
Bethel, M.A.2
George, J.3
-
19
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2016;375:311-322.
-
(2016)
New Engl J Med.
, vol.375
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
-
20
-
-
84994813253
-
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
-
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
-
(2016)
N Engl J Med
, vol.375
, pp. 1834-1844
-
-
Marso, S.P.1
Bain, S.C.2
Consoli, A.3
-
21
-
-
84929289581
-
Rationale, design, and baseline characteristics in evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
-
Bentley-Lewis R, Aguilar D, Riddle MC, et al. Rationale, design, and baseline characteristics in evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169:631-638.
-
(2015)
Am Heart J
, vol.169
, pp. 631-638
-
-
Bentley-Lewis, R.1
Aguilar, D.2
Riddle, M.C.3
-
22
-
-
85062767211
-
-
FDA Drug Shortages., Accessed November 15
-
U.S. Food & Drug Administration. FDA Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Albiglutide+%28Tanzeum%29+Injection&st=d&tab=tabs-2. Accessed November 15, 2018.
-
(2018)
-
-
-
23
-
-
85013287694
-
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
-
Mentz RJ, Bethel MA, Gustavson S, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017;187:1-9.
-
(2017)
Am Heart J
, vol.187
, pp. 1-9
-
-
Mentz, R.J.1
Bethel, M.A.2
Gustavson, S.3
-
24
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
Supplement to
-
Supplement to:Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2016;375:311-322.
-
(2016)
New Engl J Med
, vol.375
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
-
25
-
-
84926434654
-
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
-
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
-
(2014)
BMC Med Res Methodol
, vol.14
, pp. 135
-
-
Wan, X.1
Wang, W.2
Liu, J.3
Tong, T.4
-
26
-
-
85060179761
-
A data-zone scoring system to assess the generalizability of clinical trial results to individual patients
-
[published online ahead of print November 26, 2018]., [Epub ahead of print]
-
Laffin LJ, Besser SA, Alenqhat FJ. A data-zone scoring system to assess the generalizability of clinical trial results to individual patients [published online ahead of print November 26, 2018]. Eur J Prev Cardiol. 2018. https://doi.org/10.1177/2047487318815967. [Epub ahead of print].
-
(2018)
Eur J Prev Cardiol
-
-
Laffin, L.J.1
Besser, S.A.2
Alenqhat, F.J.3
-
27
-
-
85009179196
-
Computer-aided assessment of the generalizability of clinical trial results
-
Cahan A, Cahn S, Cimino JJ. Computer-aided assessment of the generalizability of clinical trial results. Int J Med Inform. 2017;99:60-66.
-
(2017)
Int J Med Inform
, vol.99
, pp. 60-66
-
-
Cahan, A.1
Cahn, S.2
Cimino, J.J.3
|